Laboratorios Richmond S.A. (RICH) Fair Value & Analysis
Healthcare · AR · Market cap 131B ARS
Fair value as of: Jul 7, 2026
From 14 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from 2,155 ARS to 841.26 ARS (−61.0%) since Jun 24, 2026. Share price +1.9% over the past month.
Below-average quality, and screening another 47% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,052 ARS). The favourable scenario is already priced in.
- Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range 117.74 ARS – 2,180 ARS · fair‑value band 829.30 ARS – 1,052 ARS · the 1,595 ARS price screens above the 841.26 ARS fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Laboratorios Richmond S.A. (RICH) currently trades at 1,595 ARS, while our model-based Fair Value estimate is 841.26 ARS, implying the stock looks roughly 47.3% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Laboratorios Richmond S.A. generated revenue of 120B ARS at a net margin of 14.0%. Revenue declined 19.8% year over year. It earns a return on equity of 16.0%. Net debt stands at 215B ARS. Fundamentals as of Jul 7, 2026
Our scenario range runs from 829.30 ARS (bear case) to 1,052 ARS (bull case); at 1,595 ARS, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 67% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -47%, RICH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (1,777 ARS) versus Asset-Based (759.14 ARS). Highest evidence: Residual Income (76).
Notify me when RICH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 25 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East.
Full company description
Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, antipsychotics, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company was incorporated in 1959 and is headquartered in Buenos Aires, Argentina.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Laboratorios Richmond S.A. reported revenue of 127B ARS in FY2025 versus 16.6B ARS in FY2021, a compound +66.2%/yr. Reported net income was 3.1B ARS in FY2025, compounding +51.2%/yr from FY2021.
RICH screens 47% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Laboratorios Richmond S.A. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Laboratorios Richmond S.A. (RICH) overvalued or undervalued?
What is the fair value of RICH?
What is the quality score of RICH?
What is the revenue of Laboratorios Richmond S.A. (RICH)?
What is the net profit margin of RICH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Laboratorios Richmond S.A. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.